Mr. Swickard’s investment supports Araceli’s work to replace animal testing with human cell science and grow Oregon’s technology industry

PORTLAND, Ore., Nov. 12, 2026 /PRNewswire/ — Araceli Biosciences, a developer of high-performance cellular imaging platforms for drug discovery, today announced that Jeff Swickard has joined the investors backing the company’s recently closed $4.5 million financing round, which is fueling record commercial momentum following two years of outsized growth, where Araceli’s revenue is projected to grow six-fold in 2026 from the same period two years ago. Mr. Swickard is excited to support Araceli’s work.

Mr. Swickard’s investment aligns with the broader shift Araceli has been enabling all year, as pharmaceutical companies move toward a tech-forward, AI-driven approach to drug discovery and adopt New Approach Methodologies (NAMs), modern methods that test whether a drug is safe and effective using human cell-based assays instead of animal models. Araceli’s Endeavor® platform makes NAMs practical at scale, helping researchers monitor how human cells respond to a drug compound and generate faster, more accurate data earlier in development, with less reliance on animal testing.

Araceli’s technology is trusted by leading pharmaceutical and life science companies, including 10 of the world’s top 20 pharmaceutical companies, with a strong presence in the Bay Area, Boston, London, and Berlin.

The investment also reflects Mr. Swickard’s commitment to growing Oregon’s technology and life sciences economy. Araceli, headquartered in Tigard, Oregon, is entering what it calls “phase two” of its commercialization: launching consumable products optimized for its growing installed base, with a broader rollout planned for 2027.

“We’re especially grateful to Jeff Swickard for his investment and for his commitment to making science more humane. His support reflects a belief that we share, which is that better science and more humane science go hand-in-hand. By helping researchers test potential drugs on human cell models earlier in development, our technology delivers faster, more accurate answers while reducing reliance on animal testing. Jeff’s investment strengthens our ability to bring that approach to more labs, and we’re proud to keep building it right here in Oregon,” said Shawn MacDonald, Araceli Biosciences Chief Financial Officer.

“We are excited to join an impressive group of investors in Araceli Biosciences, an innovative Oregon company developing technology with the potential to modernize scientific research and reduce the need for animal testing. We believe the future of science should be smarter, faster, and more humane. That future is already taking shape in Oregon, and we’re proud to be part of it,” said Jeff Swickard.

About Araceli Biosciences

Araceli Biosciences develops high-performance cellular imaging platforms designed to help researchers generate scalable, reproducible biological data for drug discovery and advanced screening applications. Founded in 2020 and spun out of Phoseon Technology in 2023, the company is headquartered in Tigard, Oregon, where most of its roughly 30 employees are based. Araceli’s Endeavor® platform and AI-driven analysis software are used by pharmaceutical and biotechnology customers across North America and Europe. Learn more at aracelibio.com.

Forward-Looking Statements

This release contains forward-looking statements, including expectations for 2026 revenue. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Araceli Biosciences undertakes no obligation to update these statements except as required by law.

Araceli Biosciences Investor and Media Contact:

corporaterelations@aracelibio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/araceli-biosciences-welcomes-jeff-swickard-as-investor-in-its-4-5-million-financing-round-302937361.html

SOURCE Araceli Biosciences